Global banking, securities and investment management group Goldman Sachs has invested US$20 million in China-based biotechnology company Ascletis. The company focuses on the discovery, development and commercialization of treatments for infectious diseases and cancer and owns four products in the clinical phase. Ascletis will use the funds to strengthen its research and development capacity and broaden the scope of its research and development pipeline.